
Cancer remains one of the leading causes of death worldwide, and yet many traditional screenings fail to detect early, subtle changes that can signal future risk. That’s where MIHA’s Aberrant Cell Growth Module stands apart.
This program uses advanced screening technologies and biomarker testing to look for early signs of abnormal cell activity — long before it becomes a diagnosable disease. Our goal isn’t to wait and react — it’s to intervene earlier, more precisely, and more effectively.

At MIHA, we use a combination of non-invasive imaging and innovative blood-based testing to identify patterns linked to:
By detecting these changes early, we can guide patients through customized plans that may help reduce their risk and improve long-term outcomes.
This module offers a comprehensive, proactive approach to early cancer surveillance — even before traditional medical systems would begin testing.

This program is designed to give you insight, clarity, and control — even when no symptoms are present.
Benefits include:
This module is ideal for:
Get in Touch Today
You don’t need to wait for a diagnosis to start protecting your future. With the Aberrant Cell Growth Module at MIHA, you’ll receive proactive, precise insights that support longevity — and potentially life-saving decisions — without guesswork.
In-Person Care in Walnut Creek | Virtual Care Available in San Francisco & Napa
Longevity & Healthy Aging Medicine
Monday – Thursday: 8:30 am – 4:30 pm
Friday: 8:30 am – 3:00 pm
Saturday & Sunday: Closed
Virtual Care Available | Relocating
Virtual Care Available | Relocating